Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01127061 · ClinicalTrials.gov registry record · NA

Study of Exercise Training in Hypertrophic Cardiomyopathy

A NA study of Cardiomyopathy, Hypertrophic, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
136
Enrollment target
2
Study locations

NCT01127061: Completed NA study of Cardiomyopathy, Hypertrophic, sponsored by University of Michigan.

NCT01127061 is a NA study of Cardiomyopathy, Hypertrophic that has completed, run by University of Michigan. The registered enrollment target is 136 participants, below the 351-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01127061, a NA study of Cardiomyopathy, Hypertrophic, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
136 participants
Enrollment target
2
Study locations

Study Summary

The investigators propose a pilot randomized controlled trial to determine the safety and potential benefits of moderate intensity exercise in patients with hypertrophic cardiomyopathy. The investigators hypotheses are that exercise parameters derived from a baseline cardiopulmonary exercise test will target an appropriately safe level of exercise intensity that will not cause significant arrhythmias or exacerbate symptoms and that exercise training for 4 months will result in significant improvements in peak oxygen consumption (peak VO2) and quality of life, with neutral effects on the clinical characteristics.

Primary Outcome

Cardiopulmonary exercise testing was performed at study enrollment and termination (4 months apart). Peak VO2 was measured at each time point in each subject and change in peak VO2 over time was calculated. The change in Peak VO2 was compared between the study arms.

Interventions

  • BEHAVIORAL Exercise training

Study Locations (2)

California

  • Stanford University - Stanford

Michigan

  • University of Michigan Cardiovascular Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2010-04
Est. Completion 2016-11
Phase NA
University of Michigan

1,327 total trials

What the finished NCT01127061 record still lists

NCT01127061 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 351-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Cardiomyopathy, Hypertrophic appearing as the primary indexed condition, and to 1 intervention - of which Exercise training is the first listed.

NCT01127061 reports a single indexed study location in California, Michigan.

Frequently Asked Questions

What is clinical trial NCT01127061 about?

NCT01127061 is a clinical study titled "Study of Exercise Training in Hypertrophic Cardiomyopathy". The investigators propose a pilot randomized controlled trial to determine the safety and potential benefits of moderate intensity exercise in patients with hypertrophic cardiomyopathy. The investigators hypotheses are that exercise parameters derived from a baseline cardiopulmonary exercise test wi...

What is the current status of trial NCT01127061?

This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2010-04. Estimated completion is 2016-11.

What conditions does trial NCT01127061 study?

This clinical trial studies the following conditions: Cardiomyopathy, Hypertrophic.

What interventions are being tested in trial NCT01127061?

The interventions under investigation include: Exercise training (BEHAVIORAL).

Who is sponsoring clinical trial NCT01127061?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01127061 being conducted?

This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiomyopathy, Hypertrophic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01127061, the US trial registry maintained by the National Library of Medicine. NCT01127061 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.